Altimmune, Inc. Common Stock (ALT) Stock Price

ALTStock

$2.20−43.44%52W

Market Cap$427.94M

P/E—

PEG Ratio32.62

Div yield—

Beta0.08

ALT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-43.04%

Price vs S&P 500 (4W)-31.40%

PEG Ratio32.62

VGM Score38.27

Book Value / Share (Quarterly)$2.44

P/TBV (Annual)3.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-83.45%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-50.98%

Net Profit Margin (TTM)-214860.98%

EPS (TTM)$-0.78

10-Day Avg Trading Volume4.13M

EPS Excl Extra (TTM)$-0.78

Revenue Growth (5Y)-65.33%

EPS (Annual)$-1.00

ROI (Annual)-33.99%

Gross Margin (Annual)100.47%

Net Profit Margin (5Y Avg)-142743.71%

Cash / Share (Quarterly)$1.68

Revenue Growth QoQ (YoY)420.00%

ROA (Last FY)-31.47%

Revenue Growth TTM (YoY)55.00%

EBITD / Share (TTM)$-0.79

ROE (5Y Avg)-51.24%

Operating Margin (TTM)-230460.98%

Cash Flow / Share (Annual)$-0.61

P/B Ratio0.90x

P/B Ratio (Quarterly)1.25x

Net Income / Employee (Annual)$-1,545,500

EV / Revenue (TTM)9748.12x

Net Interest Coverage (TTM)-15.42x

ROA (TTM)-26.96%

EPS Incl Extra (Annual)$-1.00

Current Ratio (Annual)18.55x

Quick Ratio (Quarterly)26.37x

3-Month Avg Trading Volume4.34M

52-Week Price Return-43.44%

Revenue / Employee (TTM)$500

Tangible BV / Share (Quarterly)$2.75

P/S Ratio (Annual)10437.53x

Asset Turnover (Annual)0.00x

52-Week High$6.44

Operating Margin (5Y Avg)-154341.23%

EPS Excl Extra (Annual)$-1.00

CapEx CAGR (5Y)-49.65%

Tangible BV CAGR (5Y)41.27%

26-Week Price Return-33.13%

Quick Ratio (Annual)18.35x

13-Week Price Return-23.34%

Total Debt / Equity (Annual)0.15x

Current Ratio (Quarterly)26.78x

Enterprise Value$399.67M

Revenue / Share Growth (5Y)-72.53%

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-19.74%

Revenue / Employee (Annual)$700

Pretax Margin (Annual)-216521.95%

Cash / Share (Annual)$2.47

3-Month Return Std Dev48.34%

Net Income / Employee (TTM)$-1,609,800

ROE (Last FY)-39.17%

Net Interest Coverage (Annual)-881.33x

EPS Basic Excl Extra (Annual)$-1.00

P/FCF (TTM)2377.44x

Receivables Turnover (TTM)0.02x

Total Debt / Equity (Quarterly)0.07x

EPS Incl Extra (TTM)$-0.78

Receivables Turnover (Annual)0.05x

ROI (TTM)-28.53%

P/S Ratio (TTM)10437.53x

Pretax Margin (5Y Avg)-143089.14%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$2.75

Price vs S&P 500 (52W)-58.98%

Year-to-Date Return-39.06%

5-Day Price Return-14.06%

EPS Normalized (Annual)$-1.00

ROA (5Y Avg)-45.40%

Net Profit Margin (Annual)-214860.98%

Month-to-Date Return-23.08%

EBITD / Share (Annual)$-1.07

Operating Margin (Annual)-230460.98%

LT Debt / Equity (Annual)0.15x

ROI (5Y Avg)-50.20%

LT Debt / Equity (Quarterly)0.07x

EPS Basic Excl Extra (TTM)$-0.78

P/TBV (Quarterly)3.11x

P/B Ratio (Annual)1.67x

Pretax Margin (TTM)-216521.95%

Book Value / Share (Annual)$2.03

Price vs S&P 500 (13W)-26.03%

Beta0.08x

P/FCF (Annual)778.07x

Revenue / Share (TTM)$0.00

ROE (TTM)-31.41%

52-Week Low$2.17

vGradeF

gGradeC

mGradeD

vgmGradeD

ALT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$0.13	-$0.12	+4.00%(+$0.01)
Q1 2026	May 13, 2026	-$0.25	-$0.18	+28.00%(+$0.07)
Q4 2025	Mar 5, 2026	-$0.24	-$0.27	-11.18%(-$0.03)
Q3 2025	Nov 6, 2025	-$0.27	-$0.21	+20.97%(+$0.06)
Q2 2025	Aug 12, 2025	-$0.32	-$0.27	+15.77%(+$0.05)

ALT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.06

4.13

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ALTAltimmune, Inc. Common Stock	F	C	D	10437.5x	55.0%	—	—	$2.20
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Altimmune, Inc. Common Stock

Altimmune is a clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a dual GLP-1/glucagon receptor agonist in late-stage development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The balanced 1:1 dual-receptor mechanism differentiates pemvidutide within the metabolic disease space, with the company exploring additional indications to expand its addressable market.

ALT Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.14

Revenue estimate$0

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ALT Insider Transactions

BuyAug 13, 2026
DURSO JEROME BENEDICT
Chief Executive Officer
Shares: 15,000Value: $44,250

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

RGNXREGENXBIO Inc.Biological Products
ALLOAllogene Therapeutics, Inc. Common StockBiological Products
TLRYTilray Brands, Inc. Common StockPharmaceutical Preparations
ASIXAdvanSix Inc.Plastics & Resins
AUTLAutolus Therapeutics plc American Depositary ShareBiological Products
VHIValhi, Inc.Industrial Chemicals
AGMBAgomAb Therapeutics NV American Depositary SharesBiological Products
TECXTectonic Therapeutic, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$2.17

High$6.44